logo
CareTrust REIT Closes Acquisition of Care REIT plc, Enters UK Market

CareTrust REIT Closes Acquisition of Care REIT plc, Enters UK Market

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--May 12, 2025--
CareTrust REIT, Inc. (NYSE:CTRE) ('CareTrust' or the 'Company') announced today that it has closed the acquisition of Care REIT plc, a United Kingdom-based healthcare real estate investment trust listed on the London Stock Exchange. The transaction, first announced on March 11, 2025, marks CareTrust's entrance into the UK market and represents a strategic step in the Company's mission to expand and diversify its portfolio of healthcare real estate assets.
With the completion of this transaction, CareTrust adds to its portfolio 132 care homes comprising approximately 7,500 beds and two healthcare facilities leased to the UK's National Health Service, located throughout England, Scotland, and Northern Ireland. All properties are subject to long-term, triple-net leases across 14 operators, with a weighted average remaining lease term of approximately 20.2 years and annual inflation-based rent escalators, most with a 2% floor and 4% cap.
'We are thrilled to close on the acquisition of Care REIT, marking our first M&A deal, our first international investment, and the single largest transaction in our history,' said Dave Sedgwick, President and Chief Executive Officer of CareTrust. 'Last year's exponential growth set the table for double digit growth in 2025. This strategic acquisition is transformative for our company, significantly diversifying our portfolio by operator, geography, payor source, and asset class. The acquisition strengthens our growth profile, while adding approximately $68.6 million of annualized rental revenue and a strong EBITDARM coverage ratio of 2.2x.'
Mr. Sedgwick continued, 'While we are excited about the Day 1 impact of this acquisition on our near-term outlook, we also see this transaction as an engine for growth, not just a one-off investment. With the UK's favorable demographics, strong need-based care demand, and fragmented provider landscape, we believe there is ample opportunity to scale. At the same time, we structured our UK entrance so as not to detract from investing in our core U.S. markets and operator relationships, which we remain deeply committed to expand simultaneously with the UK. The Care REIT acquisition brings with it an experienced UK-based team who is hungry to expand our footprint in that market with existing and new operators.'
'Our relationships with our new tenants are off to a strong and collaborative start, many of whom we got to know in the process of carefully evaluating our UK market entrance,' added James Callister, CareTrust's Chief Investment Officer. 'We're already finding alignment in our mutual desire to expand thoughtfully and sustainably while taking advantage of current market conditions. Many of these operators are eager to grow their own portfolios and have already engaged with us in exploring additional investment opportunities in the care home space. We believe that by leveraging our competitive advantages—deep underwriting and operating experience, pristine balance sheet, access to and cost of capital, and certainty of closing—we can help our UK operators further their missions to successfully deliver strong outcomes for their patients, residents, and communities, and for our stakeholders alike.'
Mr. Callister also reiterated that the Company's replenished US investment pipeline sits at approximately $500 million of near-term, actionable opportunities—not including larger portfolios the Company is reviewing—and that it is actively seeking additional growth opportunities in the US and abroad.
2025 Guidance and Liquidity
In conjunction with the closing of the Care REIT acquisition, Bill Wagner, CareTrust's Chief Financial Officer, updated management's 2025 guidance to include the impact of the transaction, projecting net income of approximately $1.42 to $1.45 per common share, normalized FFO of approximately $1.75 to $1.78 per common share, and normalized FAD of approximately $1.75 to $1.78 per common share. He noted that the 2025 guidance is based on diluted weighted-average common shares outstanding of 190.6 million and assumes the following:
'We are excited by the near- and long-term growth potential the Care REIT transaction unlocks, and we believe it positions us to deliver compounding value to stakeholders over time,' said Bill Wagner, Chief Financial Officer. 'After a period of integration, which we anticipate lasting through 2025, we expect to achieve annual run rate synergies of approximately $5 million. Incorporating the realization of these savings, we anticipate the fully-synergized acquisition to be approximately 9.4% accretive to normalized FFO per share and 5.7% accretive to normalized FAD per share, both relative to the guidance in place when the acquisition was announced on March 11, 2025.'
Based on the British Pound Sterling to U.S. Dollar exchange rate on May 9, 2025, the terms of the Care REIT acquisition represent a total purchase price of approximately $840.5 million, of which $595.4 million represents cash consideration to acquire Care REIT common shares, together with the assumption of $245.1 million net debt and exclusive of transaction fees. Mr. Wagner noted that the Company intends to pay off the assumed debt and recapitalize the portfolio through a combination of cash on hand, a draw from its revolving credit facility, and a new $500 million unsecured term loan expected to be finalized in the second quarter, subject to ordinary closing conditions. Prior to completion of this refinancing, net debt-to-normalized EBITDA is expected to be below 2.0x.
Piper Sandler Ltd and JP Morgan Securities LLC acted as financial advisors and Jones Day acted as legal advisor to CareTrust.
About CareTrust™
CareTrust REIT, Inc. is a self-administered, publicly-traded real estate investment trust engaged in the ownership, acquisition, development and leasing of skilled nursing, seniors housing and other healthcare-related properties. With a portfolio of long-term net-leased properties spanning the United States and United Kingdom, and a growing portfolio of quality operators leasing them, CareTrust is pursuing both external and organic growth opportunities across the US and internationally. More information about CareTrust REIT is available at www.caretrustreit.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical statements of fact and statements regarding the Company's intent, belief or expectations, including, but not limited to, statements regarding the following: future financial and financing plans; strategies related to the Company's business and its portfolio, including acquisition opportunities and disposition plans; expectations regarding the integration of Care REIT plc; growth prospects; operating and financial performance; and the performance of the Company's tenants and operators and their respective facilities.
Words such as 'anticipate,' 'believe,' 'could,' 'expect,' 'estimate,' 'intend,' 'may,' 'plan,' 'seek,' 'should,' 'will,' 'would,' and similar expressions, or the negative of these terms, are intended to identify such forward-looking statements, though not all forward-looking statements contain these identifying words. The Company's forward-looking statements are based on management's current expectations and beliefs, and are subject to a number of risks and uncertainties that could lead to actual results differing materially from those projected, forecasted or expected. Although the Company believes that the assumptions underlying these forward-looking statements are reasonable, they are not guarantees and the Company can give no assurance that its expectations will be attained. Factors which could have a material adverse effect on the Company's operations and future prospects or which could cause actual results to differ materially from expectations include, but are not limited to: (i) our ability to integrate Care REIT's operations into our business and achieve the benefits expected to result from the acquisition; (ii) the ability and willingness of our tenants and borrowers to meet and/or perform their obligations under the agreements we have entered into with them, including without limitation, their respective obligations to indemnify, defend and hold us harmless from and against various claims, litigation and liabilities; (iii) the risk that we may have to incur additional impairment charges related to our assets held for sale if we are unable to sell such assets at the prices we expect; (iv) the impact of healthcare reform legislation, including minimum staffing level requirements, on the operating results and financial conditions of our tenants and borrowers; (v) the ability of our tenants and borrowers to comply with applicable laws, rules and regulations in the operation of the properties we lease to them or finance; (vi) the ability and willingness of our tenants to renew their leases with us upon their expiration, and the ability to reposition our properties on the same or better terms in the event of nonrenewal or in the event we replace an existing tenant, as well as any obligations, including indemnification obligations, we may incur in connection with the replacement of an existing tenant; (vii) the availability of and the ability to identify (a) tenants who meet our credit and operating standards, and (b) suitable acquisition opportunities and the ability to acquire and lease the respective properties to such tenants on favorable terms; (viii) the ability to generate sufficient cash flows to service our outstanding indebtedness; (ix) access to debt and equity capital markets; (x) fluctuating interest and foreign currency exchange rates; (xi) the impact of public health crises, including significant COVID-19 outbreaks as well as other pandemics or epidemics; (xii) the ability to retain our key management personnel; (xiii) the ability to maintain our status as a real estate investment trust ('REIT'); (xiv) changes in the U.S. tax law and other state, federal or local laws, whether or not specific to REITs; (xv) other risks inherent in the real estate business, including potential liability relating to environmental matters and illiquidity of real estate investments; and (xvi) any additional factors included in our Annual Report on Form 10-K for the year ended December 31, 2024, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, including in the sections entitled 'Risk Factors' in Item 1A of such reports, as such risk factors may be amended, supplemented or superseded from time to time by other reports we file with the SEC.
The Company expressly disclaims any obligation to update or revise any information in this press release, including forward-looking statements, whether to reflect any change in the Company's expectations, any change in events, conditions or circumstances, or otherwise.
As used in this press release, unless the context requires otherwise, references to 'CTRE,' 'CareTrust,' 'CareTrust REIT' or the 'Company' refer to CareTrust REIT, Inc. and its consolidated subsidiaries. GAAP refers to generally accepted accounting principles in the United States of America.
Non-GAAP Financial Measures
Funds from Operations ('FFO'), as defined by the National Association of Real Estate Investment Trusts ('Nareit'), and Funds Available for Distribution ('FAD') are important non-GAAP supplemental measures of operating performance for a REIT. Because the historical cost accounting convention used for real estate assets requires straight-line depreciation except on land, such accounting presentation implies that the value of real estate assets diminishes predictably over time. Since real estate values have historically risen or fallen with market and other conditions, presentations of operating results for a REIT that uses historical cost accounting for depreciation could be less informative. Thus, Nareit created FFO as a supplemental measure of operating performance for REITs that excludes historical cost depreciation and amortization, among other items, from net income, as defined by GAAP.
FFO is defined by Nareit as net income computed in accordance with GAAP, excluding gains or losses from dispositions of real estate investments, real estate related depreciation and amortization and real estate impairment charges, adjustments for the share of consolidated joint ventures, and adjustments for unconsolidated partnerships and joint ventures. Noncontrolling interests' pro rata share information is prepared by applying noncontrolling interests' actual ownership percentage for the period and is intended to reflect noncontrolling interests' proportionate economic interest in the financial position and operating results of properties in our portfolio. The Company computes FFO attributable to CareTrust REIT, Inc. in accordance with Nareit's definition.
FAD attributable to CareTrust REIT, Inc. is defined as FFO attributable to CareTrust REIT, Inc. excluding noncash income and expenses, such as amortization of stock-based compensation, amortization of deferred financing fees, amortization of above and below market intangibles, amortization of lease incentives, the effects of straight-line rent, adjustments for the share of consolidated joint ventures and non-cash interest income. The Company considers FAD attributable to CareTrust REIT, Inc. to be a useful supplemental measure to evaluate the Company's operating results excluding these income and expense items to help investors, analysts and other interested parties compare the operating performance of the Company between periods or as compared to other companies on a more consistent basis.
In addition, the Company reports Normalized FFO attributable to CareTrust REIT, Inc. and Normalized FAD attributable to CareTrust REIT, Inc., which adjust FFO and FAD for certain revenue and expense items that the Company does not believe are indicative of its ongoing operating results, such as write-off of deferred financing costs, provision for loan losses, non-routine transaction costs, provision for doubtful accounts and lease restructuring, loss on extinguishment of debt, extraordinary incentive plan payment, unrealized loss on other real estate related investments, recovery of previously reversed rent, lease termination revenue and property operating expenses. By excluding these items, investors, analysts and our management can compare Normalized FFO and Normalized FAD between periods more consistently.
While FFO, Normalized FFO, FAD and Normalized FAD are relevant and widely-used measures of operating performance among REITs, they do not represent cash flows from operations or net income as defined by GAAP and should not be considered an alternative to those measures in evaluating the Company's liquidity or operating performance. FFO, Normalized FFO, FAD and Normalized FAD do not purport to be indicative of cash available to fund future cash requirements.
Further, the Company's computation of FFO, Normalized FFO, FAD and Normalized FAD may not be comparable to FFO, Normalized FFO, FAD and Normalized FAD reported by other REITs that do not define FFO in accordance with the current Nareit definition or that interpret the current Nareit definition or define FAD differently than the Company does.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250512202355/en/
CONTACT: CareTrust REIT, Inc.
(949) 542-3130
[email protected]
KEYWORD: EUROPE UNITED STATES UNITED KINGDOM NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: COMMERCIAL BUILDING & REAL ESTATE CONSTRUCTION & PROPERTY HOSPITALS REIT HEALTH INSURANCE OTHER HEALTH MANAGED CARE GENERAL HEALTH HEALTH RESIDENTIAL BUILDING & REAL ESTATE
SOURCE: CareTrust REIT, Inc.
Copyright Business Wire 2025.
PUB: 05/12/2025 06:01 AM/DISC: 05/12/2025 06:01 AM
http://www.businesswire.com/news/home/20250512202355/en
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Liverpool to agree fantastic transfer in next HOURS
Liverpool to agree fantastic transfer in next HOURS

Yahoo

time12 minutes ago

  • Yahoo

Liverpool to agree fantastic transfer in next HOURS

Liverpool are closing in on a fantastic transfer that should be wrapped up in the next few hours. This one deserves applause. Liverpool are reportedly closing in on the transfer of Giovanni Leoni from Parma. The Reds are in desperate need of a new centre-back and the teenager fits the bill. Jarell Quansah's exit has left the squad light, after all. Liverpool sold the defender for a very good price but didn't immediately move for a replacement. Shop the LFC Store LFC x adidas Shop the home range today! LFC x adidas Shop the goalkeeper range today LFC x adidas Shop the new adidas range today! Boosting the numbers at centre-back is also a priority because of Ibrahima Konate's situation. He's now in the final year of his contract and a move to Real Madrid is on the cards. Liverpool hope to renew his contract but if they don't, they won't want to leave themselves scrambling for someone in 2026. Then there's Virgil van Dijk - now 34 and coming to the end of his elite level. Investing in youth is absolutely crucial and Leoni is certainly that. 🔴 Shop the LFC 2025/26 adidas away range Liverpool close in on Giovanni Leoni Ben Jacobs reports that a deal between Liverpool and Parma for Leoni 'could be finalised in 24 hours or less'. He says the parties are all very close to an agreement and we won't be waiting long. At this point, Leoni looks destined for Anfield where he'll get to learn under his idol, Van Dijk. Virtually everything about this transfer makes sense for Liverpool, in fact. Leoni is still only 18 but broke into Parma's starting XI last season, appearing 14 times in Serie A. He's unquestionably one of the best wonderkid centre-backs in world football - if not the best.

Wegovy and Zepbound patients are resorting to these cost-saving measures to stay on the weight-loss drugs
Wegovy and Zepbound patients are resorting to these cost-saving measures to stay on the weight-loss drugs

Fast Company

time13 minutes ago

  • Fast Company

Wegovy and Zepbound patients are resorting to these cost-saving measures to stay on the weight-loss drugs

Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but as more U.S. insurers restrict coverage people are trimming costs by stretching doses or forgoing expenditures like vacations to pay for the medication out of pocket. A half dozen doctors who spoke with Reuters said insurance coverage has tightened in 2025 as many employers drop it for the expensive GLP-1 drugs. While patients on these medications are counseled on proper diet and exercise, clinical trials show that people who stop taking these drugs are apt to regain weight. Novo Nordisk's Wegovy and Eli Lilly's Zepbound are weekly injections with U.S. insurer list prices of more than $1,000 a month. For customers willing to pay cash, both drugmakers will ship directly for $499 a month if refills are purchased at fixed intervals. 'A significant number of my patients now pay cash,' said Dr. Nidhi Kansal, an obesity specialist at Northwestern Medicine in Chicago. 'People find a way to scrounge up $6,000 a year, which sucks, because that's a vacation or two.' Subscribe to the Daily newsletter. Fast Company's trending stories delivered to you every day Privacy Policy | Fast Company Newsletters More than a billion people worldwide are obese, according to the U.N. World Health Organization, which has said the GLP-1 drugs could help end the obesity pandemic. 'A KIND OF PURGATORY' A tech industry job change for Yelena Kibasova, a 40-year-old who lives in the Minneapolis area, meant loss of coverage for her Zepbound prescription that helped her achieve and maintain a 150-pound (68-kg) weight loss. GLP-1 patient Yelena Kibasova, 40, poses in this undated handout picture. [Photo: @morethanmyweight/Handout via Reuters] 'My new company does not cover GLP-1s, so now I am in a kind of purgatory,' Kibasova said. 'I stopped doing my nails. I stopped doing my hair. Those things are not as important as me staying at a healthy weight.' The doctors interviewed by Reuters said patients once leery about long-term obesity treatment are now more comfortable staying on a drug. The doctors said that conversations about temporary use happen only when a patient is trying to lose a certain amount of weight for issues such as fertility treatment or an organ transplant. These obesity specialists said they are hopeful that competition will help bring down prices as new weight-loss options emerge, including new oral drugs that may be available next year. Lilly last week announced trial results for its easier-to-manufacture pill, which was shown to cut patient weight by 12.4%, a few percentage points less than injected drugs. The company hopes to launch it in August 2026. Kenneth Custer, Lilly's head of cardiometabolic health, told Reuters the pill is being tested in several settings, including as a maintenance therapy. Custer declined to comment on how it might be priced. MEDICATION FOR MAINTENANCE Dr. Anne Peters, an endocrinologist at Keck Medicine USC in Los Angeles, said it is important that patients who reach their weight-loss goal not stop a prescription 'cold turkey,' so the dose can be tapered down over several months. Peters said about a third of her patients are able to reduce their dose and maintain weight loss, while the rest need to stay on the medication. An analysis of U.S. pharmacy insurance claims found that nearly two-thirds of patients who started on Wegovy or Zepbound in 2024 were still on the medications a year later. advertisement Peters said she uses 'every technique in the book' to secure insurance coverage for patients, but noted that a growing number of plans no longer pay for the treatments, and patients have to pay out-of-pocket. U.S. pharmacies supply self-injection pens pre-loaded with doses of Wegovy or Zepbound. Lilly's direct-to-consumer service also offers vials. 'Some patients can stretch out the vials longer. Get 15 mg, and then give a 10 mg dose for instance,' Dr. Peters said, noting that the drug's instructions advise that such an approach should not be taken. Doses of 5 mg, 10 mg and 15 mg are recommended for weight-loss maintenance. Patients also are turning to lower-cost compounded versions of the GLP-1 drugs, or are even mixing them at home with raw ingredients, both of which Peters and other doctors advise against due to safety concerns. Dr. Angela Fitch, former president of the Centennial, Colorado-based Obesity Medicine Association and chief medical officer at online primary care provider Knownwell, said nobody wants to be on a medication, but patients who respond to a GLP-1 drug 'really don't want to go off of it when they recognize that it has such a value to them.' Both Wegovy and Zepbound were first launched, under the brand names Ozempic and Mounjaro, as diabetes treatments. The class has been linked to a range of benefits, including improved heart health and less sleep apnea. Fitch said the most common reason for her patients to stop taking a GLP-1 drug is loss of insurance coverage. She said her experience is that about 10% of patients are able to reach a target weight and maintain it without further treatment. 'We are in a dip where people are dropping coverage,' Fitch said, adding that the direct-to-consumer options are an 'upper-ish middle-class thing.' —Deena Beasley, Reuters

Escondido, Calif., a Showcase for Fire-Resilient Building
Escondido, Calif., a Showcase for Fire-Resilient Building

New York Times

time15 minutes ago

  • New York Times

Escondido, Calif., a Showcase for Fire-Resilient Building

Nestled in a valley in the foothills of the Santa Ana Mountains about 30 miles from both San Diego and the nearest Pacific beach, Escondido, Calif., has grown from an agricultural community known for its grapes and avocados into a town that attracts people looking for a more affordable version of the Southern California lifestyle. It's hotter than the coastal cities and is known for its traffic, both downsides. But Gina Mancuso, a real estate agent with eXp Realty of California, said government investments in traffic abatement, such as freeway express lanes, have brought the average commute to San Diego or nearby Carlsbad, Calif., to less than 30 minutes. Location: San Diego County, 30 miles north of San Diego, 100 miles south of Los Angeles Population: 148,119 (U.S. Census Bureau estimate) Area: 37 square miles Housing: 52 percent homeownership rate The vibe: This diverse town, founded in 1888, has a walkable downtown, parks, lakes, wineries and a center for the arts. However, Escondido, which translates from Spanish to 'hidden,' can't hide from the high risk of wildfire in the region. To address the problem, the homebuilder KB Home is constructing 64 homes in its new Dixon Trail development that meet high levels of fire preparedness developed by researchers at the Insurance Institute for Business and Home Safety. A community of single-family homes, one-third of which have already sold, Dixon Trail has houses that range from about 2,000 to 3,000 square feet and have base prices from $1.067 million to $1.342 million. A 2024 demonstration of fire-resilient building inspired the project, said Steve Ruffner, president and regional general manager for KB Home Coastal in San Diego. Want all of The Times? Subscribe.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store